Severe rhabdomyolysis associated with raltegravir use

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

“…Creatine kinase elevation (11 patients) was the most frequent grade 3-4 laboratory adverse event. Although a recent case report acknowledged a case of severe rhabdomyolysis associated with raltegravir use [31], the proportion of patients with creatine kinase elevation in the BENCHMRK trials was not in the raltegravir treatment group than in the control group. In our study, all patients with creatine kinase elevations were asymptomatic, and none discontinued study treatment.…”

Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy

“…In particular, those patients that are taking zidovudine, didanosine, or integrase inhibitors are particularly susceptible. 18,20,21 To the best of our knowledge, there is only one reported case of a 47-year-old HIVpositive female on HAART, including tenofovir, developing symptomatic rhabdomyolysis, evidence of proximal tubular dysfunction, and AKI. 22 However, this episode of AKI was not severe enough to necessitate hemodialysis.…”

Implications of integrase inhibitors for HIV-infected transplantation recipients: Raltegravir and dolutegravir (S/GSK 1349572)

“…One must pay attention to concomitant use of RAL with other drugs (e.g. statins) that can cause rabdomyolysis (13)(14)(15)(16)(17). In addition, one can not entirely exclude the possibility that the concern for rabdomyolysis caused by concomitant use of RAL and statins may be further enhanced by CNIs due to disturbance of statin uptake into the liver by organic anion transporting polypeptides (18).…”